Levobupivacaina Kabi

Levobupivacaine Hydrochloride, the active ingredient in Levobupivacaina Kabi, is a local anesthetic (amide type) presented as a sterile solution for epidural, infiltration and intrathecal use. It provides reversible nerve block for surgical and diagnostic procedures in adult patients. GNH USA supplies Levobupivacaina Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levobupivacaina Kabi is a local anesthetic used in regional anesthesia techniques. - Epidural anesthesia: produces analgesia for lower‑body surgeries and obstetric procedures. - Spinal (intrathecal) anesthesia: provides rapid, dense block for lower‑limb and pelvic operations. - Peripheral nerve block: enables targeted anesthesia of specific nerves for orthopedic or trauma surgery. - Infiltration anesthesia: allows local pain control for soft‑tissue procedures and postoperative analgesia.

Adverse reactions may occur following administration of Levobupivacaina Kabi.

Common Side Effects: - Hypotension: transient drop in blood pressure. - Bradycardia: slowed heart rate. - Dizziness or light‑headedness. - Nausea or vomiting. - Metallic taste in the mouth. - Headache.

Serious or Rare Side Effects: - Cardiac arrhythmia or cardiac arrest. - Seizures or central nervous system toxicity. - Respiratory depression or apnea. - Prolonged motor block. - Allergic reaction including rash or anaphylaxis. - Methemoglobinemia.

Prior to using Levobupivacaina Kabi, clinicians should consider several safety measures. - Assess cardiovascular status: monitor blood pressure and heart rate before and during administration. - Evaluate hepatic function: dose may need adjustment in severe liver disease. - Review patient medication list: avoid concurrent use with other potent local anesthetics. - Use incremental dosing: inject slowly and observe for signs of toxicity. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Levobupivacaina Kabi can interact with other drugs that affect cardiac or central nervous system function.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., bupivacaine): additive cardiotoxicity. - Beta‑adrenergic blockers: may enhance bradycardia and hypotension. - Inhalational anesthetics (e.g., halothane): increase risk of neurotoxicity.

Moderate Interactions (Monitor Closely): - Opioids: may potentiate central nervous system depression. - Muscle relaxants: may increase neuromuscular blockade. - Diuretics: can exacerbate hypotension when combined.